OMER241220C2000
- 5.50
- 0.000.00%
Omeros Newsroom
Omeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial Challenges
Express News | Omeros Corporation Presents Phase 2 Zaltenibart Data At ASH Meeting, Supporting Dose Selection For Upcoming Phase 3 Clinical Trials In Paroxysmal Nocturnal Hemoglobinuria, With Enrollment Set For Early 2025
AppLovin, MicroStrategy, and 28 Other Stocks That Could Be Bubbles
Jim Cramer Prefers FedEx Over This Delivery Giant That 'Screwed Up A Lot Of Holiday Seasons'
Replimune REPL +35% BLA Submission; Omeros OMER +41% BLA Update
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday
Express News | Omeros Corp - FDA Requests Additional Sensitivity Analyses for Sap
Express News | Omeros Corp - Independent Expert Statistical Group to Conduct Analyses
Express News | Omeros Corp - Receives FDA Response on Revised Sap for Narsoplimab Bla
Express News | Omeros Corporation Provides Update on Progress Toward Bla Resubmission
While Institutions Invested in Omeros Corporation (NASDAQ:OMER) Benefited From Last Week's 54% Gain, Retail Investors Stood to Gain the Most
Omeros Shares Hit 52-Week High on Plan to Resubmit Narsoplimab Application
Omeros Up Over 49%, On Pace for Largest Percent Increase Since February 2023 -- Data Talk
Express News | Cantor Fitzgerald Reiterates Neutral on Omeros
Rodman & Renshaw Maintains Omeros(OMER.US) With Buy Rating, Cuts Target Price to $9
Express News | Rodman & Renshaw Initiates Coverage On Omeros With Buy Rating, Announces Price Target of $9
Needham Maintains Omeros(OMER.US) With Hold Rating
Omeros Analyst Ratings
Omeros (OMER) Gets a Hold From Needham
Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript Summary